MIZUHO MEDY CO.,LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,630 JPY | +0.74% |
|
-3.95% | +3.69% |
| 2021 | Mizuho Medy Co.,Ltd.(TSE:4595) added to S&P Global BMI Index | CI |
| 2020 | Mizuho Medy Co.,Ltd.(TSE:4595) dropped from S&P Global BMI Index | CI |
| Sales 2024 * | 9.5B 58.8M | Sales 2025 * | 10B 61.89M | Capitalization | 30.82B 191M |
|---|---|---|---|---|---|
| Net income 2024 * | 2.65B 16.4M | Net income 2025 * | 2.83B 17.51M | EV / Sales 2024 * | 2.04 x |
| Net cash position 2024 * | 11.47B 70.99M | Net cash position 2025 * | 12.44B 76.97M | EV / Sales 2025 * | 1.84 x |
| P/E ratio 2024 * |
11.6
x | P/E ratio 2025 * |
10.9
x | Employees | 180 |
| Yield 2024 * |
4.33% | Yield 2025 * |
4.64% | Free-Float | 53.62% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.62% | ||
| 1 week | -3.95% | ||
| Current month | +0.37% | ||
| 1 month | -6.30% | ||
| 3 months | -1.18% | ||
| 6 months | +0.18% | ||
| Current year | +3.69% |
1 week
1 603.00
1 727.50
1 month
1 603.001 770.00
Current year
1 552.501 910.00
1 year
1 005.001 945.00
3 years
887.002 137.50
5 years
512.002 137.50
10 years
180.002 137.50
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 79 | 77-11-01 | |
Tadashi Imamura
CTO | Chief Tech/Sci/R&D Officer | 65 | 84-03-31 |
Toshio Kambara
BRD | Director/Board Member | 60 | 94-09-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Katsumi Sasaki
BRD | Director/Board Member | 79 | 15-02-28 |
| Founder | 79 | 77-11-01 | |
Tadashi Imamura
CTO | Chief Tech/Sci/R&D Officer | 65 | 84-03-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-02 | 1,630 | +0.74% | 40 100 |
| 24-07-02 | 1,618 | -0.19% | 74,200 |
| 24-07-01 | 1,621 | -0.06% | 103,600 |
| 24-06-28 | 1,622 | -3.51% | 166,700 |
| 24-06-27 | 1,681 | -1.41% | 180,800 |
Delayed Quote Japan Exchange, July 02, 2024 at 09:12 pm EDT
More quotes
MIZUHO MEDY CO., LTD. is a Japan-based company principally engaged in-vitro diagnostic pharmaceuticals business. The Company mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.
Calendar
2024-08-07
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +3.69% | 191M | |
| -10.83% | 11.36B | |
| -19.13% | 7.17B | |
| +26.61% | 5.55B | |
| +3.47% | 5.33B | |
| -20.49% | 3.65B | |
| +6.88% | 2.59B | |
| -66.28% | 2.23B | |
| -14.18% | 2.2B | |
| +29.36% | 2.17B |
- Stock Market
- Equities
- 4595 Stock
